| 1 |
CD319
(
SLAMF7
) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab |
|
| | Kah Teong Soh,Joseph D. Tario,Theresa Hahn,Jens Hillengass,Philip L. McCarthy,Paul K. Wallace | | | Cytometry Part B: Clinical Cytometry. 2020; | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry |
|
| | Kah Teong Soh,Paul K. Wallace | | | Current Protocols in Cytometry. 2019; 90(1) | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Diagnosis of chronic lymphoproliferative disorders by flow cytometry using four-color combinations for immunophenotyping: A proposal of the brazilian group of flow cytometry (GBCFLUX) |
|
| | M. M. Sales,S. I. A. C. P. Ferreira,M. R. V. Ikoma,A. F. Sandes,M. P. Beltrame,N. S. Bacal,M. C. A. Silva,M. Malvezzi,I. G. H. Lorand-Metze,A. Orfao,M. Yamamoto | | | Cytometry Part B: Clinical Cytometry. 2016; | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Optimal strategy for obtaining routine chromosome analysis by using negative fractions of CD138 enriched plasma cells |
|
| | Veronica Ortega,Gihan Mohamed,William Ehman,Meiqing Zhu,Christina Mendiola,Gopalrao Velagaleti | | | Cancer Genetics. 2015; | | | [Pubmed] [Google Scholar] [DOI] | |
|
